Protocol Ledger

NCT03496766 · Phase II · TERMINATED

Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS

Interventional Phase II clinical trial protocol NCT03496766 sponsored by Spanish Lung Cancer Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-07 Enrollment: 9 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03496766
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)9 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03496766
Protocol FieldVerified Registry Value
NCT IdentifierNCT03496766
Consolidated Lead SponsorSpanish Lung Cancer Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment9 participants (ACTUAL)
Registered Start Date2018-05-07
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03496766
Hospital Research SiteLocationSite Profile
Hospital General Universitario de ElcheElche, SpainOpen Hospital Dossier ->
Complejo Hospitalario de NavarraPamplona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI